2019
DOI: 10.1136/bcr-2018-228892
|View full text |Cite
|
Sign up to set email alerts
|

Myopathy in a 61-year-old Hispanic man

Abstract: A 61-year-old Hispanic man presented to a county hospital for subacute progressive weakness, heliotrope rash and dysphagia. There was initial suspicion for dermatomyositis (DM) given the history; however, the physical exam was not consistent. An MRI followed by a muscle biopsy revealed necrotising autoimmune myositis and anti-3-hydroxy-3-methylglutary-coenzyme A-reductase antibody titers returned positive; the patient was diagnosed with necrotising autoimmune myositis. He was treated with corticosteroids and i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 28 publications
(30 reference statements)
0
1
0
Order By: Relevance
“…22,23 In our study, there was a notorious improvement in the SLEDAI-2K scores when compared to partially improved SLEDAI-2K scores in one patient with SLE and myositis in a previous study. 12 On the other hand, several case reports and evidence of IVIG in isolated inflammatory myopathies have been described, 24,25 suggesting IVIG’s benefits where muscular involvement is present. On the other hand, literature about IVIG in gastrointestinal manifestations is restricted to case reports with satisfactory outcomes when these are indicated as adjuvant or third-line therapy.…”
Section: Discussionmentioning
confidence: 99%
“…22,23 In our study, there was a notorious improvement in the SLEDAI-2K scores when compared to partially improved SLEDAI-2K scores in one patient with SLE and myositis in a previous study. 12 On the other hand, several case reports and evidence of IVIG in isolated inflammatory myopathies have been described, 24,25 suggesting IVIG’s benefits where muscular involvement is present. On the other hand, literature about IVIG in gastrointestinal manifestations is restricted to case reports with satisfactory outcomes when these are indicated as adjuvant or third-line therapy.…”
Section: Discussionmentioning
confidence: 99%